Annual General Meeting Presentation 2017

November 17, 2017 Kerry Rowe

AGM Presentation 2017

Post navigation

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate
Chairman’s Address to Shareholders 2019 Annual General Meeting
AGM 2019 Presentation

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Annual General Meeting Presentation 2017

Related Posts

Prana Announces A$6.0 Million Capital Raising

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Prana’s PBT2 Reverses Memory Loss in Normal Aging